Study of ADG206 in Subjects With Advanced/Metastatic Solid Tumors

Phase 1 Active not recruiting 14 enrolled Adagene Inc

NaSequentialOpen-labelTreatment

Summary

ADG206 is an activatable prodrug form of a fully human monoclonal antibody (mAb) of the immunoglobulin G1 (IgG1) subclass that specifically targets cluster of differentiation 137 (CD137) (also known as 4-1BB) as a co-stimulatory receptor agonist for the treatment of advanced malignancies.

Timeline

Start: 2023-02-13
Primary completion: 2025-06-25
Completion: 2026-08-30

Publications

Singh R, Kim YH, Lee SJ, Eom HS, Choi BK. 4-1BB immunotherapy: advances and hurdles. Exp Mol Med. 2024 Feb;56(1):32-39. doi: 10.1038/s12276-023-01136-4. Epub 2024 Jan 4.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ADG206	Unknown	—	Intravenous

Indications

No indication recorded.